GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer GSK has acquired exclusive rights from Syndivia for an antibody-drug conjugate (ADC) targeting advanced prostate cancer in a …
TCT 2025: ShortCUT Trial Compares Cutting Balloon Angioplasty and Intravascular Lithotripsy (IVL) for Calcified Coronary Artery Disease Th…
Building the Future, Respecting the Past Tbilisi is undergoing a dynamic transformation, with sustainable urban development taking center …
Cygnet Energy Enters into Agreement to Acquire Kiwetinohk Energy Corp. Cygnet Energy Ltd., a private exploration and production company, h…
Novartis to Acquire Avidity Biosciences Novartis will buy Avidity Biosciences for US$12 billion, gaining its RNA-based therapeutic platfor…
Why Frustrated Boomers Are the Senior Living Industry’s Biggest Potential Disruptors This story is part of your SHN+ subscription. Senior …